Category

Newsroom
The Law on Planning and Construction, enacted in 2009, stipulated that after September 2010, companies acquired in privatization, bankruptcy proceedings or debt collection proceedings would not be able to obtain...
Read More
We set forth an outline of the most significant amendments to the Serbian Law on Corporate Income Tax, which came into force on 25 December 2012. Read more
Read More
Serbia has made one further step towards foreign exchange liberalization, with the Parliament’s adoption of a new set of amendments to the Law on Foreign Exchange on 15 December 2012. Read...
Read More
BDK is proud of its IP and Competition blogs being introduced on the ‘IPKat’, one of the most prominent IP blogs internationally.
Read More
Serbia has made one further step towards foreign exchange liberalization, with the Parliament’s adoption of a new set of amendments to the Law on Foreign Exchange on 15 December 2012. Read...
Read More
Osnovana srpsko-alžirska firma “Salsef” za izgradnju skladišta – Planirane investicije u 2013. oko 30 mil EUR Alžirska državna firma “Frigomedit” i kompanija ITN iz Beograda potpisale su danas Sporazum o...
Read More
Titan Machinery Inc. (NASDAQ:TITN) announced today that it has entered into a definitive agreement with VAIT-Voest Alpine Intertrading to acquire a CaseIH dealership in the Vojvodina region of Serbia. The...
Read More
BDK’s Bogdan Ivanisevic wrote for Balkan Insight a legal analysis of the recent judgment by the Appeals Chamber of the International Criminal Tribunal for the Yugoslavia in the case Prosecutor v. Gotovina & Markac. The...
Read More
BDK’s Bogdan Ivanišević, who is a former researcher for Human Rights Watch and a consultant for the International Center for Transitional Justice, wrote for the Balkan Insight a legal analysis of the recent...
Read More
Watson Pharmaceuticals has completed its 4.25 billion Euro acquisition of Swiss competitor Actavis Group, making Watson the third-largest generic drug company worldwide. BDK advised Watson on their acquisition of Actavis’...
Read More
1 2

ARCHIVE